A Phase 2 clinical trial of TVB-3567 (ASC-60) in moderate to severe acne
Latest Information Update: 23 Mar 2026
At a glance
- Drugs ASC 60 (Primary)
- Indications Acne
- Focus Therapeutic Use
Most Recent Events
- 23 Mar 2026 New trial record
- 11 Mar 2026 According to Sagimet Biosciences media release, company anticipates starting a Phase 2 clinical trial with TVB-3567 in moderate to severe acne patients in 2026